Takamichi Ito Selected Research

Interleukin-33

9/2023	Regulatory Mechanism of the IL-33-IL-37 Axis via Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
3/2020	Aryl Hydrocarbon Receptor Activation Downregulates IL-33 Expression in Keratinocytes via Ovo-Like 1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takamichi Ito Research Topics

Disease

23	Neoplasms (Cancer) 03/2024 - 04/2013
21	Melanoma (Melanoma, Malignant) 07/2023 - 02/2012
7	Hemangiosarcoma (Angiosarcoma) 11/2023 - 01/2016
7	Atopic Dermatitis (Atopic Eczema) 09/2023 - 01/2017
6	Inflammation (Inflammations) 09/2023 - 01/2018
6	Neoplasm Metastasis (Metastasis) 07/2023 - 12/2013
5	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2023 - 01/2018
4	Diabetic Nephropathies (Diabetic Nephropathy) 02/2007 - 01/2004
3	Extramammary Paget Disease (Paget Disease, Extramammary) 03/2024 - 01/2021
3	Body Weight (Weight, Body) 01/2023 - 02/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2024 - 03/2021
2	Skin Neoplasms (Skin Cancer) 11/2023 - 01/2022
2	Carcinoma (Carcinomatosis) 01/2022 - 01/2022
2	Drug Eruptions (Drug Eruption) 07/2021 - 05/2014
2	Ischemia 05/2021 - 07/2017
2	Pruritus (Itching) 09/2020 - 03/2020
2	Wounds and Injuries (Trauma) 12/2019 - 01/2004
2	Skin Ulcer 12/2019 - 04/2015
2	Psoriatic Arthritis 08/2019 - 11/2018
2	Carcinogenesis 01/2017 - 12/2013
2	Nevus (Nevi) 12/2013 - 06/2013
1	Xeroderma Pigmentosum (Kaposi's Disease) 02/2024
1	Skin Diseases (Skin Disease) 09/2023
1	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2023
1	Peripheral Nervous System Diseases (PNS Diseases) 02/2023
1	Basal Cell Carcinoma (Rodent Ulcer) 09/2022
1	Margins of Excision 01/2022
1	COVID-19 02/2021
1	Lichen Planus (Lichen Ruber Planus) 02/2021
1	Fever (Fevers) 02/2021

Drug/Important Bio-Agent (IBA)

8	Immune Checkpoint InhibitorsIBA 04/2023 - 01/2018
6	Immunoconjugates (Immunoconjugate)IBA 03/2024 - 01/2021
6	NectinsIBA 03/2024 - 08/2020
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2004
5	Cell Adhesion MoleculesIBA 03/2024 - 08/2020
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2023 - 01/2021
4	NivolumabIBA 01/2023 - 05/2021
4	Interleukin-17 (Interleukin 17)IBA 09/2020 - 01/2018
3	Thiostrepton (Gargon)IBA 01/2024 - 01/2016
3	taxaneIBA 07/2023 - 02/2023
3	enfortumab vedotinIBA 01/2022 - 08/2020
3	Blood Glucose (Blood Sugar)IBA 07/2009 - 02/2006
3	CreatinineIBA 02/2007 - 01/2004
2	Paclitaxel (Taxol)FDA LinkGeneric 11/2023 - 02/2023
2	Interleukin-33IBA 09/2023 - 03/2020
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 09/2023 - 01/2017
2	AntibodiesIBA 01/2023 - 08/2022
2	IpilimumabIBA 01/2023 - 01/2023
2	Surface Antigens (Surface Antigen)IBA 01/2022 - 07/2021
2	sacituzumab govitecanIBA 01/2022 - 07/2021
2	monomethyl auristatin EIBA 01/2022 - 01/2021
2	Interleukin-13IBA 09/2020 - 12/2019
2	Filaggrin ProteinsIBA 06/2018 - 01/2017
2	Small Interfering RNA (siRNA)IBA 07/2016 - 01/2016
2	Transcription Factors (Transcription Factor)IBA 07/2016 - 01/2016
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 12/2013 - 01/2004
2	Matrix Metalloproteinases (MMPs)IBA 12/2013 - 01/2004
2	Keratins (Keratin)IBA 06/2013 - 04/2013
2	PyridoxamineIBA 07/2009 - 02/2007
2	Glucose (Dextrose)FDA LinkGeneric 07/2009 - 01/2004
2	Advanced Glycation End ProductsIBA 02/2007 - 02/2006
2	AlbuminsIBA 02/2007 - 02/2006
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2007 - 01/2004
1	Voriconazole (Vfend)FDA LinkGeneric 02/2024
1	Plasminogen Activator Inhibitor 1IBA 11/2023
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2023
1	ParaffinIBA 07/2023
1	Formaldehyde (Formol)FDA Link 07/2023
1	Phenobarbital (Luminal)FDA Link 07/2023
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 05/2023
1	difamilastIBA 05/2023
1	Phosphodiesterase 4 InhibitorsIBA 05/2023
1	Therapeutic UsesIBA 03/2023
1	ErbB Receptors (EGF Receptor)IBA 02/2023
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2023
1	Docetaxel (Taxotere)FDA Link 02/2023
1	DDTIBA 02/2023
1	KN 93IBA 01/2023
1	pembrolizumabIBA 01/2023
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2023
1	5-((glucopyranosyloxy)methyl)uracilIBA 09/2022
1	AntigensIBA 01/2022
1	src-Family KinasesIBA 01/2022
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 07/2021
1	Cyclin-Dependent Kinase 4IBA 07/2021
1	binimetinibIBA 03/2021
1	encorafenibIBA 03/2021
1	dabrafenibIBA 02/2021
1	trametinibIBA 02/2021
1	CytokinesIBA 03/2020
1	Interleukin-1 (Interleukin 1)IBA 03/2020
1	ChemokinesIBA 01/2020
1	InterleukinsIBA 01/2020

Therapy/Procedure

20	Therapeutics 11/2023 - 01/2019
3	Drug Therapy (Chemotherapy) 07/2023 - 08/2017
2	Molecular Targeted Therapy 01/2021 - 06/2016
1	Chemoradiotherapy 02/2023
1	Immunotherapy 01/2023
1	Mohs Surgery (Mohs' Micrographic Surgery) 01/2022
1	Operative Surgical Procedures 02/2020